# CRISPR Gene Editing Shows Promise in Protecting Donor Cells During Blood Cancer Treatment
Researchers have demonstrated a novel application of CRISPR gene editing that protects donor stem cells from cancer-killing drugs, potentially solving a major obstacle in treating aggressive blood malignancies. The approach involves removing the CD33 protein from transplanted stem cells before infusion, allowing doctors to deploy targeted therapies against leukemia and other blood cancers without harming the very cells patients depend on for survival.
The study enrolled 30 patients receiving donor stem cell transplants for blood cancers. Researchers used CRISPR base editing to delete the CD33 gene from the donor cells prior to transplantation. CD33 serves as a surface marker on blood cancer cells, making it an established target for immunotherapies. One such therapy, gemtuzumab ozogamicin, binds to CD33 and kills cancer cells expressing the protein.
The problem clinicians faced before this research was clear. When patients received standard donor stem cell transplants after chemotherapy, they became vulnerable to leukemia relapse. Administering CD33-targeted cancer drugs killed the malignant cells but also destroyed the healthy donor cells providing blood cell production. This trade-off left patients without adequate bone marrow function.
By genetically removing CD33 from donor cells before transplant, researchers created cells resistant to CD33-targeted therapies. The edited cells successfully engrafted in all 30 patients, meaning they took hold and began producing blood cells as intended. Patients then received CD33-targeted cancer treatment without the edited donor cells being affected. The malignant cancer cells, still expressing CD33, remained vulnerable to elimination.
This represents a meaningful advance in allogeneic stem cell transplantation, where patients receive cells from matched donors. The procedure has proven curative for many blood cancers but carries substantial relapse risk. Donor lymphocyte infusions and other strategies attempt to prevent recurrence but carry their own complications.
CRISPR base editing differs from earlier CRISPR approaches by making precise single-letter changes to DNA without creating double-strand breaks. This results in fewer off-target edits and greater cellular safety. The researchers chose CD33 as their target because the protein is not essential for normal blood cell production. Patients missing CD33 function remain healthy, though they show reduced numbers of certain immune cells.
The trial confirms that edited cells persist long-term and maintain normal function after transplant. No serious adverse events related to the CRISPR editing were observed. Whether the strategy actually reduces relapse rates compared to historical controls remains to be determined through longer follow-up and larger studies.
Researchers conducting the trial did not use an untreated control group, meaning doctors cannot yet say definitively that the approach outperforms standard transplantation with CD33-targeted therapy. Future trials will need to compare outcomes in patients receiving edited versus unedited donor cells to establish clinical benefit.
The work opens possibilities for similar CRISPR-based approaches targeting other antigens on blood cancers. Researchers could edit donor cells to remove markers on other leukemias, allowing broader therapeutic application. The strategy may also extend to solid tumors if appropriate targets exist on both cancer and immune cells.